Stock listing
NASDAQ:ASPE Aspen Neuroscience, Inc. Stock
Home listing (NASDAQ) of Aspen Neuroscience, Inc.
Follow Aspen Neuroscience, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:ASPE
$12.42 USD +0.41 (+3.4%)
Close on Nov 20, 2026
- Day range
- $12.17 – $13.19 USDNov 20, 2026
- Volume
- 130,038 sharesNov 20, 2026
- Market cap
- $361.2M USDAt the close on Nov 20, 2026 · price × 29.08M shares outstanding
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:ASPE · Home | $12.42 USD | +0.41 (+3.4%) | 130,038 | $12.24 | $13.19 | $12.17 | $12.01 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Oct 29, 2026 – Nov 20, 2026 · NASDAQ:ASPE · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $12.42 | +0.41 | +3.4% | $12.24 | $13.19 | $12.17 | 130,038 | |
| $12.01 | +0.01 | +0.1% | $12.00 | $13.37 | $11.76 | 289,107 | |
| $12.00 | -0.23 | -1.9% | $12.21 | $12.80 | $11.81 | 256,815 | |
| $12.23 | -0.36 | -2.9% | $12.45 | $12.61 | $12.00 | 216,346 | |
| $12.59 | -1.02 | -7.5% | $14.00 | $14.07 | $12.07 | 173,274 | |
| $13.61 | -0.21 | -1.5% | $13.95 | $14.42 | $12.62 | 267,365 | |
| $13.82 | +1.01 | +7.9% | $13.04 | $14.40 | $12.22 | 290,515 | |
| $12.81 | +0.41 | +3.3% | $12.65 | $13.15 | $12.10 | 279,364 | |
| $12.40 | -0.04 | -0.3% | $12.81 | $13.15 | $11.92 | 215,456 | |
| $12.44 | +0.68 | +5.8% | $11.52 | $12.72 | $11.47 | 174,201 | |
| $11.76 | -1.00 | -7.8% | $13.11 | $13.11 | $11.25 | 185,200 | |
| $12.76 | +0.47 | +3.8% | $11.92 | $12.95 | $11.20 | 312,700 | |
| $12.29 | -0.75 | -5.8% | $13.00 | $14.49 | $12.00 | 639,700 | |
| $13.04 | -1.85 | -12.4% | $14.65 | $14.65 | $12.63 | 596,500 | |
| $14.89 | -0.11 | -0.7% | $14.70 | $14.90 | $11.60 | 1,322,500 | |
| $15.00 | — | — | $15.00 | $15.00 | $15.00 | 0 |
- Ticker
- NASDAQ:ASPE
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Aspen Neuroscience, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Where Aspen Neuroscience, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:ASPE · Home listing · This page | NASDAQ | United States | USD |
| BOATS:ASPE | BOATS | United States | USD |
Valuation
Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $288.8M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- Under 6 months of closes
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Aspen Neuroscience, Inc. · NASDAQ:ASPE | US$361.2M | US$288.8M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Rezolute, Inc. · NASDAQ:RZLT | US$379.2M | US$289.9M | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.28 |
| Phathom Pharmaceuticals, Inc. · NASDAQ:PHAT | US$378.8M | US$359.8M | n/a | 1.3× | n/a | n/a | −30.2% | n/a | 1.08 |
| Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509 | US$370.8M | US$380.6M | 4.5× | 2.5× | 4.2× | 2.9× | 53.3% | 0.8× | n/a |
| PureTech Health PLC · LSE:PRTC | US$364.5M | US$160.6M | n/a | 34.5× | n/a | 0.9× | n/a | 0.1× | n/a |
| Puma Biotechnology Inc · NASDAQ:PBYI | US$364.5M | US$255.9M | 15.3× | 1.1× | 5.8× | 2.5× | 10.3% | 0.0× | 0.88 |
| Lumosa Therapeutics Co Ltd · TPEX:6535 | US$362.5M | US$343.2M | n/a | 329× | n/a | 9.7× | n/a | 0.0× | n/a |
| Alector, Inc. · NASDAQ:ALEC | US$347.6M | US$208.9M | 8.4× | 1.2× | 4.9× | 3.0× | 23.9% | 0.0× | 1.72 |
| Gongwin Biopharm Holdings Co., Ltd. · TPEX:6617 | US$347.4M | US$296.7M | n/a | 232× | n/a | 4.9× | −389.6% | 0.0× | n/a |
| AbClon, Inc. · KRX:174900 | US$346.2M | US$319.2M | n/a | 80.9× | n/a | 8.8× | −328.3% | 0.0× | n/a |
| Onconic Therapeutics, Inc. · KRX:476060 | US$344.5M | US$298.0M | 19.1× | 4.9× | n/a | 5.4× | 29.5% | 0.0× | n/a |
| Median of the others | US$363.5M | US$297.3M | 11.8× | 4.9× | 4.9× | 4.4× | 10.3% | 0.0× | 1.18 |
Team and board
Officers
| Officer | Role |
|---|---|
| Damien McDevitt | President and Chief Executive Officer |
| Dalen Meeter | Chief Financial Officer |
| Jeff Boerneke | General Counsel and Secretary |
| Andrés Bratt-Leal | Senior Vice President, Research & Development |
| Cindy Perettie | Executive Vice President and Global Head |
| Jennifer Whitaker | Vice President, Human Resources |
| Samantha Murphy | Senior Vice President, Corporate Development |
| Ana Sousa | Chief Regulatory Officer |
| Caryn Peterson | Chief Development Officer, Gossamer |
| Faheem Hasnain | Aspen Executive Chairman |
| Kim Raineri | Chief Technology Officer |
| Lisa Johnson-Pratt | Sasineprocel Development Lead and Chief Commercial Officer |
| Revati Shreeniwas | Chief Medical Officer |
| Xiaokui Zhang | Chief Scientific Officer |
Board
| Director | Role |
|---|---|
| Faheem Hasnain | Aspen Executive Chairman |
| Damien McDevitt | President and Chief Executive Officer |
| Peter Thompson | Director |
| Tom Daniel | Director |
IPO
Priced at US$15.00 a share on Oct 29, 2026.
- Price
- US$15.00 a share
- Shares offered
- 9,375,000 shares of common stock
- Offering size
- US$140.6 million
- Underwriters' option
- Up to 1,406,250 more shares
- Listing
- ASPE on the Nasdaq Global Select Market
- Underwriters
- Leerink Partners, UBS Investment Bank, Piper Sandler, Stifel, Oppenheimer & Co. · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Mar 30, 2026 |
| Filed publicly | Oct 9, 2026 |
| Amended twice | Newest Oct 26, 2026 |
| Shares registered with an exchange | Oct 29, 2026 |
| Declared effective by the SEC | Oct 29, 2026 |
| Final prospectus, with the price | Oct 30, 2026 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Oct 30, 2026 |
| EFFECT · Notice that a registration is effective | Oct 29, 2026 |
| CERT · Exchange's certificate of listing | Oct 29, 2026 |
| 8-A12B · Registration of shares for listing on an exchange | Oct 29, 2026 |
| S-1/A · Registration statement, amended | Oct 26, 2026 |
| S-1/A · Registration statement, amended | Oct 22, 2026 |
| S-1 · Registration statement | Oct 9, 2026 |
| DRS/A · Draft registration statement, amended | Jun 10, 2026 |
| DRS/A · Draft registration statement, amended | May 12, 2026 |
| DRS · Draft registration statement | Mar 30, 2026 |
Open IPO · From the cover of the final prospectus (424B4) filed Oct 30, 2026
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | 0 | 0 |
| Research and development | 41.8M | 35.6M |
| Selling, general and administrative | 17.1M | 17.4M |
| Operating income | -59.3M | -53.5M |
| Depreciation and amortization | 3.96M | 3.51M |
| EBITDA | -55.3M | -49.9M |
| Income before tax | -62.1M | -48.6M |
| Net income | -62.1M | -48.6M |
| Earnings per share, basic | -2.13 | -1.67 |
Balance sheet
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash and equivalents | 82.1M | 15.2M |
| Short-term investments | 28.6M | 42.5M |
| Current assets | 112.4M | 59.6M |
| Total assets | 143.7M | 90.2M |
| Accounts payable | 2.64M | 853.0K |
| Current liabilities | 14.3M | 14.0M |
| Total liabilities | 360.7M | 247.9M |
| Shareholders' equity | -217.1M | -157.7M |
| Shares outstanding | 29.1M | 29.1M |
Cash flow
| Line | FY2025 | FY2024 |
|---|---|---|
| Cash from operations | -52.8M | -44.2M |
| Capital spending | -9.69M | -2.58M |
| Free cash flow | -62.5M | -46.7M |
| Cash from financing | 115.5M | 457.0K |
| Change in cash | 66.9M | -23.1M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| SCHEDULE 13D · Big-stake notice | Nov 9, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 9, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D · Big-stake notice | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 6, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 4, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 3, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 2, 2026 | Insider trade | SEC |
All 39 filings
Cap table
Built by 6ix from Aspen Neuroscience, Inc.’s releases
- Common shares
- 29,078,600
- Fully diluted
- 29,078,600
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 29,078,600 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 29,078,600 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Peter Thompson Other companies: Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Edgewise Therapeutics, Inc. (Chairman and Co-Founder · Since at least Mar 25, 2021); ARS Pharmaceuticals, Inc. (Director · Since at least Dec 3, 2020); Corvus Pharmaceuticals, Inc. (CO-FOUNDER · Since at least Mar 22, 2016); Janux Therapeutics, Inc. (Director · Jun 10, 2021 – Jun 14, 2022 · Past); Decibel Therapeutics Inc (Director · Feb 11, 2021 – Jun 17, 2022 · Past); PMV Pharmaceuticals, Inc. (Director · Sep 24, 2020 – Jun 2, 2021 · Past); Prevail Therapeutics Inc (Director · Jun 19, 2019 – Jan 22, 2021 · Past); Synthorx Inc (Director · Dec 6, 2018 – Jan 23, 2020 · Past); Principia Biopharma Inc (Director · Sep 13, 2018 – Sep 13, 2018 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – May 18, 2024 · Past); Adaptimmune Therapeutics PLC (Director · Jan 1, 2016 – Jun 4, 2018 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Jul 21, 2015 · Past); Anthera Pharmaceuticals Inc (Director · Feb 1, 2011 – May 8, 2012 · Past); Trubion Pharmaceuticals Inc (President and CEO, Director · Oct 17, 2006 – Aug 27, 2009 · Past) | General Partner · Since at least Nov 2, 2026 |
| Faheem Hasnain Other companies: Gossamer Bio, Inc. (Co-Founder, Chairman, and Chief Executive Officer · Since at least Feb 7, 2019); Kura Oncology, Inc. (Lead Independent Director · Since at least Apr 23, 2015); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Tocagen Inc (Director · Apr 12, 2017 – Oct 4, 2019 · Past); Immunic, Inc. (Director · Aug 11, 2016 – Sep 13, 2018 · Past); Ambit Biosciences Corp (Director · May 15, 2013 – Nov 10, 2014 · Past); Receptos Inc (President & CEO, Director · May 8, 2013 – Aug 25, 2015 · Past); Somaxon Pharmaceuticals Inc (Director · Sep 16, 2010 – Dec 31, 2012 · Past); Facet Biotech Corp (President & CEO, Director · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (President & CEO, Director · Oct 1, 2008 – Oct 1, 2008 · Past) | Aspen Executive Chairman · Since at least Nov 2, 2026 |
| Andrew Spaventa Other companies: Singular Genomics Systems Inc (Chief Executive Officer, Director · May 26, 2021 – Feb 21, 2025 · Past) | Director · Since at least Nov 2, 2026 |
| Caryn Peterson Other companies: Gossamer Bio, Inc. (Chief Development Officer · Since at least Apr 16, 2021) | Chief Development Officer, Gossamer · Since at least Nov 5, 2026 |
| Dalen Meeter Other companies: Singular Genomics Systems Inc (Chief Financial Officer · May 26, 2021 – Feb 21, 2025 · Past) | Chief Financial Officer · Since at least Nov 5, 2026 |
| Ana Sousa | Chief Regulatory Officer · Since at least Nov 5, 2026 |
| Andrés Bratt-Leal | Senior Vice President, Research & Development · Since at least Nov 5, 2026 |
| Cindy Perettie | Executive Vice President and Global Head · Since at least Nov 4, 2026 |
| Damien McDevitt | President and Chief Executive Officer · Since at least Nov 5, 2026 |
| Jeff Boerneke | General Counsel and Secretary · Since at least Nov 4, 2026 |
All 17 people
| Person | Seat |
|---|---|
| Jennifer Whitaker | Vice President, Human Resources · Since at least Nov 4, 2026 |
| Kim Raineri | Chief Technology Officer · Since at least Nov 5, 2026 |
| Lisa Johnson-Pratt | Sasineprocel Development Lead and Chief Commercial Officer · Since at least Nov 5, 2026 |
| Revati Shreeniwas | Chief Medical Officer · Since at least Nov 5, 2026 |
| Samantha Murphy | Senior Vice President, Corporate Development · Since at least Nov 5, 2026 |
| Tom Daniel | Director · Since at least Nov 4, 2026 |
| Xiaokui Zhang | Chief Scientific Officer · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Aspen Neuroscience, Inc.